.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted to debut on everyone market.The Eli Lilly-partnered biotech hopes to provide on the Nasdaq under the sign "BIOA," according to documents filed with the Stocks and also Swap Payment. The company has certainly not publicly shared an expected monetary amount for the offering.The clinical-stage firm touts lead prospect azelaprag, an orally supplied small molecule slated to enter stage 2 testing in combination along with semaglutide-- marketed through Novo Nordisk under trademark name Wegovy for weight loss-- in the initial fifty percent of next year. Semaglutide is actually also marketed as Ozempic and Rybelsus through Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is designed to combine properly with GLP-1 medications, enhancing weight-loss while maintaining muscle mass. The investigational medication was located to be well-tolerated one of 265 individuals all over 8 phase 1 tests, depending on to BioAge.Formerly, BioAge got the support of Lilly to operate a trial blending azelaprag along with the Significant Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetic issues as Mounjaro and Zepbound for weight management. The partners are actually presently conducting a phase 2 test of azelaprag as well as tirzepatide, with topline results anticipated in the third fourth of 2025.The biotech is additionally planning a blood insulin sensitiveness proof-of-concept trial analyzing azelaprag as a monotherapy in the first one-half of upcoming year to assist prospective indication growth. Moreover, the company intends to ask the FDA for consent in the 2nd one-half of 2025 to launch human screening for an NLRP3 inhibitor targeting metabolic ailments and also neuroinflammation.BioAge's expected relocate to the public market follows a slight uptick in organized biotech IPOs coming from Bicara Rehabs and also Zenas Biopharma. Zooming out, the recent IPO yard is a "mixed photo," along with top quality providers still debuting on everyone markets, just in minimized varieties, depending on to PitchBook.